VRTX Stock Analysis: Buy, Sell, or Hold?
VRTX - Vertex Pharmaceuticals Inc
$453.06
4.77 (1.06%)
▲
5d:
+5.94%
30d:
+1.98%
90d:
-1.77%
BUY
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 04, 2026
0d
Get Alerted When VRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: VRTX shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: VRTX shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$690.09
Based on 8.3% avg growth
INTRINSIC VALUE TODAY
$428.49
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VRTX is currently trading at $453.06, which is considered extended relative to its 30-day fair value range of $427.13 to $441.44. The stock's valuation (Forward PE: 21.0) is in line with its historical norms (21.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This pessimistic expectation contrasts with the company's recent 61.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, VRTX is in a strong downtrend. The price is approaching resistance at $454.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $549.50 (+21.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VRTX is in a strong downtrend. The price is approaching resistance at $454.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: VRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $549.50 (+21.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$427.13 -
$441.44
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.3% below Wall St target ($549.50)
Trading Range Analysis
30-Day Trading Range
$427.13 -
$441.44
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$412.27
Resistance Level
$454.79
Current Trend
Strong Downtrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.99
Wall Street Target
$549.50
(+21.3%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
61.4%
Profit Margin
35.5%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
21.0 vs 21.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$448.98
(-1%)
2-Year Target
$444.94
(-2%)
3-Year Target
$440.94
(-3%)
3-Yr Target (if PE normalizes)
(PE: 21→22)
$451.69
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 12.6%)
$679.09
(+50%)
Base:
(SPY PE: 21.0, Growth: 12.6%)
$646.69
(+43%)
Bear:
(PE: 17.8, Growth: 12.6%)
$549.68
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 25.84 | Current EPS (TTM): $16.84
Bull Case
$613.61
(+35%)
Analyst growth 28.2%, PE expands to 28.4
Base Case
$557.82
(+23%)
Market implied 28.2%, PE stable at 25.8
Bear Case
$295.92
(-35%)
Severe decline -20.0%, PE contracts to 22.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.0 to 21.5
Stabilization Target:
$464.11
(+2.4%)
PE Expansion Potential:
+2.4%
Share & Embed Analysis
Last updated: May 14, 2026 9:46 AM ET
Data refreshes hourly during market hours. Next update: 10:46 AM
Data refreshes hourly during market hours. Next update: 10:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Joy Liu
SELL
978 shares
2026-04-01
Carmen Bozic
SELL
2329 shares
2026-03-13
Amit Sachdev
SELL
1846 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 64 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
Advanced VRTX Option Strategies
Professional options setups generated by AI based on today's VRTX price and gamma walls.
